- Trial phase
- Preclinical / Phase 1
- Time to market
- Unknown, NMRA-898 is still in preclinical/Phase 1 development. If Phase 1 data is positive, Phase 2 trials would follow, meaning potential approval is likely 5+ years away, assuming successful development.
- Why 5/10
- The next hard catalyst is Phase 1 data readout for NMRA-898 in schizophrenia, expected in H2 2026 (per Q2 2026 earnings release on Aug 14, 2026). As an early-stage Phase 1 readout at a company with multiple pipeline programs, this is a moderate-impact catalyst, positive data could validate the M4 approach but Phase 1 readouts rarely drive the kind of binary move that later-stage data would.
Watch for NMRA-898 Phase 1 data readout in H2 2026 (likely Q4 2026), which will be the first clinical proof-of-concept for this M4 agonist in schizophrenia. Positive data could validate the program and drive a re-rating, but Phase 1 safety/tolerability readouts are early-stage and high-risk. The stock also has a larger binary catalyst in the NMRA-335140 (navacaprant) Phase 3 MDD data readout, which is the more consequential near-term event.
Price Chart
Executive Summary
NMRA-898 is Neumora Therapeutics' lead M4 muscarinic receptor agonist program for schizophrenia, currently in early-stage development (preclinical/Phase 1). The drug targets the same mechanism as KarXT (Cobenfy), the first new class of schizophrenia treatment approved in decades. Phase 1 data is expected in H2 2026, which could serve as an early validation catalyst. Neumora (Nasdaq: NMRA) trades at ~$1.04 with a ~$320M market cap, supported by a bullish analyst consensus (mean PT $6.14) and notable institutional accumulation in Q2 2026. However, the stock faces headwinds from heavy insider selling by the COO, elevated short volume (~45%), and the early-stage nature of the program. NMRA-898 is one of several pipeline assets; the company's more advanced navacaprant (NMRA-335140) Phase 3 MDD program represents a larger binary catalyst.
How It Works
NMRA-898 is an oral drug designed to activate the M4 muscarinic receptor in the brain. This receptor is a key target for schizophrenia because it modulates dopamine signaling without the side effects of traditional antipsychotics. The mechanism is the same one validated by KarXT (Cobenfy), the first new class of schizophrenia drug approved in decades. By selectively targeting M4, NMRA-898 aims to treat positive and negative symptoms of schizophrenia while avoiding the off-target side effects (like constipation, dry mouth, urinary retention) that limit KarXT.
Trial Status
NMRA-898 is described as Neumora's "lead M4 program in schizophrenia" (per Q4 2025 earnings). Phase 1 data readout is expected in H2 2026 (per Q2 2026 earnings update on Aug 14, 2026). No clinical trial records for NMRA-898 were found in the SecBot database, suggesting it has not yet entered formal clinicaltrials.gov-listed studies or is in very early Phase 1.
The Two-Sided Case
Upcoming Catalysts
- Phase 1 data readout for NMRA-898 in schizophrenia, expected H2 2026 (likely Q4 2026)
- NMRA-511 MAD expansion cohort data in Alzheimer's agitation, expected Q4 2026
- NMRA-215 IND submission, planned Q4 2026
- Navacaprant (NMRA-335140) Phase 3 KOASTAL-2 and -3 MDD data readouts, timing TBD (trials completed May 2026, results pending)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Neumora Therapeutics, Inc. PRESS-RELEASE NMRA ·Originating report